Codexis News

Codexis Initiated at Overweight by Cantor Fitzgerald

Codexis Initiated at Overweight by Cantor Fitzgerald

Dow JonesMay 30 08:03

Cantor Fitzgerald Starts Codexis With Overweight Rating, $11 Price Target

Codexis (CDXS) has an average rating of buy and price targets ranging from $3 to $11, according to analysts polled by Capital IQ. Price: 3.3473, Change: +0.16, Percent Change: +4.93

MT NewswiresMay 30 07:40

Codexis to Participate in Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held

GlobeNewswireMay 22 15:25

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, "Sustainable API

GlobeNewswireMay 20 15:05

Stifel Nicolaus Reaffirms Their Buy Rating on Codexis (CDXS)

TipRanksMay 20 06:55

Codexis (CDXS) Gets a Buy From Craig-Hallum

TipRanksMay 14 08:05

Codexis Successfully Synthesizes An Oligonucleotide Via An Enzymatic Route To Support RNA-Based Therapeutics Manufacturing

Codexis Successfully Synthesizes An Oligonucleotide Via An Enzymatic Route To Support RNA-Based Therapeutics Manufacturing

BenzingaMay 14 05:12

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to

GlobeNewswireMay 14 05:00

Is Codexis (NASDAQ:CDXS) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu

Simply Wall StMay 5 08:38

Codexis First Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceMay 4 08:45

Benchmark Reiterates Buy on Codexis, Maintains $9 Price Target

Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:CDXS) with a Buy and maintains $9 price target.

BenzingaMay 3 12:31

Codexis Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 127.27% Benchmark → $9 Reiterates Buy → Buy 02/29/2024 127.27% Benchmark → $9 Upgrades Hold → B

BenzingaMay 3 12:29

Codexis Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.

Codexis Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.

BenzingaMay 3 10:59

Earnings Call Summary | Codexis(CDXS.US) Q1 2024 Earnings Conference

The following is a summary of the Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript:Financial Performance:Codexis reported Q1 2024 total revenues of $17.1 million, an increase of 32% year-over-yea

Futu NewsMay 3 08:41 · Conference Call

Benchmark Co. Sticks to Their Buy Rating for Codexis (CDXS)

TipRanksMay 3 06:38

Q1 2024 Codexis Inc Earnings Call

Yahoo FinanceMay 3 05:47

Codexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...

Yahoo FinanceMay 3 03:01

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 2 19:24

Codexis Inc (CDXS) Q1 2024 Earnings: Surpasses Revenue Forecasts With Strategic Advances

Yahoo FinanceMay 2 17:06

Codexis Reiterates 2024 Product Revenue Guidance $38M-$42M Excluding Revenue Related To PAXLOVID

Codexis Reiterates 2024 Product Revenue Guidance $38M-$42M Excluding Revenue Related To PAXLOVID

BenzingaMay 2 16:40